Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Published on November 11, 2024

Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
View Resource

Help Patients Face the Realities of Life with Metastatic Breast Cancer Through Expose MBC

Published on: July 15, 2024

Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

Visit http://Expose-MBC.com and share this site with your patients.

ESR1 Mutations in ER+/HER2 - Metastatic Breast Cancer

Published on: June 26, 2024

Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

Learn more about this ESR1 mutation at http://Knowesr1.com.

Diagnosis and Treatment of Hematologic Cancer

Published on: June 26, 2024

BPDCN is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.

Learn more about this hematologic disease at https://BPDCNinfo.com.

PharmaEssentia Educational Resource

PharmaEssentia SOURCE helps connect patients to ongoing support, education, and resources throughout their treatment journey.

• Navigating insurance and financial hurdles
• Educating about treatment initiation, including injection training
• Offering ongoing patient engagement and resources

Click here to enroll in SOURCE.

Click here for our copay assistance program.

New Resources for Acute Myeloid Leukemia Care Providers

To improve outcomes for patients with acute myeloid leukemia, especially those who do not receive a transplant, the Association of Cancer Care Centers (ACCC), with support from Bristol Myers Squibb, has partnered with the HealthTree Foundation for Acute Myeloid Leukemia to develop a suite of resources, including:

• Cancer Buzz Podcast Series
• ACCC Buzz Educational Blog Series
• Comprehensive Effective Practices Guide

Access Resources Now

Small Cell Lung Cancer: A guide for patients and their families

Published on: Mar 24, 2024

This resource was created by Patient Resource and GO2 for Lung Cancer and produced with support from Jazz Pharmaceuticals to provide patients and their loved ones with comprehensive information to guide them throughout their journey with small cell lung cancer. A Spanish-speaking version is available via download.
Free copies of this resource can be obtained by ordering it by:

💻 Visiting: https://okt.to/W7ib3U

✉️ Emailing: prp@patientresource.com

📞 Calling: 800-497-7530